

Pharmesis Reports 13.9% Revenue Growth to RMB27.2 Million in 1H2025

- Increase in revenue was mainly driven by a higher contribution from non-prescribed TCM drugs
- Gross profit increased by 18.9% to RMB10.3 million with gross profit margin improved 1.6 percentage points to 38.0%
- Declared special interim dividend of 1.00 Singapore cent per share to mark its 20th anniversary

Singapore, 14 August 2025 – Pharmesis International Ltd. (“**Pharmesis**” or the “**Company**” and, together with its subsidiaries, the “**Group**”), manufacturer of pharmaceutical products in China announced that the Group has reported a 13.9% revenue growth to RMB27.2 million for the half year ended 30 June 2025 (“**1H2025**”).

RMB 'million	1H2025	1H2024	% Change
Revenue	27.2	23.9	13.9
Gross profit	10.3	8.7	18.9
Gross profit margin	38.0	36.4	1.6 p.p
Net loss attributable to the equity holders of the Company	(1.4)	(3.5)	n.m

The increase in revenue was driven by a higher contribution of RMB4.1 million from non-prescribed TCM drugs, mainly from stronger sales of Er Ding products. This was partially offset by a RMB0.8 million decline in revenue from prescribed western drugs, due to lower sales of Anethole Trithione (“ATT”) products.

In line with the revenue growth, gross profit rose 18.9% to RMB10.3 million in 1H2025, compared to RMB8.7 million in 1H2024. Gross profit margin improved from 36.4% in 1H2024 to 38.0% in 1H2025, mainly due to higher margins from ATT products.

Selling and distribution costs declined from RMB5.6 million in 1H2024 to RMB5.3 million in 1H2025, mainly due to lower marketing expenses. Administrative costs rose 8.6%, from RMB5.7 million in 1H2024 to RMB6.2 million in 1H2025, driven by higher personnel expenses and increased allowance for expected credit losses. Finance costs also inched up from RMB352,000 in 1H2024 to RMB359,000 in 1H2025, mainly due to higher interest expenses.

As a result, the Group’s net loss after tax attributable to equity holders of the Company of has narrowed to RMB1.4 million in 1H2025, as compared to a net loss after tax of RMB3.5 million in 1H2024.

Despite the challenging economic environment, the Group has declared special interim dividend of 1.00 Singapore cent per share to mark its 20th anniversary and as a gesture of appreciation for the continued loyalty and support of its shareholders.

Mr. Wu Xuedan, Executive Director and Chief Executive Officer of Pharmesis, commented, “The overall business environment remains challenging, and we have been actively seeking opportunities to drive stronger sales performance. This includes expanding our sales channels through digital marketing and e-commerce to reach a broader customer base, create multiple touchpoints for customers and enhance their purchasing experience. By diversifying our distribution strategy, we aim to tap into new markets and improve accessibility to our products. Moving forward, we will continue to operate prudently, focusing on boosting sales and managing costs effectively.”

About Pharmesis International Ltd.

Listed on the Main Board of the Singapore Exchange in October 2004, Pharmesis International Ltd. specialises in the manufacture of pharmaceutical products, including western medicine and Traditional Chinese Medicine (“TCM”).

Under our two subsidiaries, Chengdu Kinna Pharmaceutical Co., Ltd and Sichuan Longlife Pharmaceutical Co., Ltd, we specialise in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products for the treatment of illnesses relating to the liver and gall bladder. Additionally, the Group’s business also includes research and development, production, sale and marketing of pharmaceutical products.

Our pharmaceutical products are sold in the People’s Republic of China (“PRC”) under the “国嘉” brand. Our main products are ATT, Gulin Gansu and Er Ding granules. Our Gulin Gansu is under the National TCM Protection List and is also the first TCM formulated products to be awarded the “Product of Designation of Origin and Geographical Indications of the PRC”.

For more information, please visit <https://www.pharmesis.com/>

**Issued for and on behalf of Pharmesis International Ltd.
by Woodnote Consulting**

Yong Jing Wen
E: jingwen@woodnoteconsulting.com
T: (65) 9860 3047